3.8 Review

Hyperbaric oxygen therapy in experimental and clinical stroke

期刊

MEDICAL GAS RESEARCH
卷 6, 期 2, 页码 111-118

出版社

WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/2045-9912.184721

关键词

hyperbaric oxygen therapy; hyperbaric oxygen preconditioning; stroke; experimental studies; clinical studies; ischemia; cerebrovascular disease

资金

  1. Suzhou Key Medical Center of China [Szzx201501]
  2. National Natural Science Foundation of China [81571115, 81422013, 81471196]
  3. Scientific Department of Jiangsu Province in China [BL2014045]
  4. Suzhou Government in China [LCZX201301, SZS201413, SYS201332]
  5. Priority Academic Program Development of Jiangsu Higher Education Institutions

向作者/读者索取更多资源

Stroke, which is defined as a neurologic deficit caused by sudden impaired blood supply, has been considered as a common cause of death and disability for decades. The World Health Organization has declared that almost every 5 seconds a new stroke occurs, placing immense socioeconomic burdens. However, the effective and available treatment strategies are still limited. Additionally, the most effective therapy, such as thrombolysis and stenting for ischemic stroke, generally requires a narrow therapeutic time window after the event. A large majority of patients cannot be admitted to hospital and receive these effective treatments for reperfusion timely. Hyperbaric oxygen therapy (HBOT) has been frequently applied and investigated in stroke since 1960s. Numerous basic and clinical studies have shown the beneficial efficacy for neurological outcome after stroke, and meanwhile many underlying mechanisms associated with neuroprotection have been illustrated, such as cerebral oxygenation promotion and metabolic improvement, blood-brain barrier protection, anti-inflammation and cerebral edema, intracranial pressure modulation, decreased oxidative-stress and apoptosis, increased vascular and neural regeneration. However, HBOT in human stroke is still not sufficiently evidence-based, due to the insufficient randomized double-blind controlled clinical studies. To date, there are no uniform criteria for the dose and session duration of HBOT in different strokes. Furthermore, the additional effect of HBOT combined with drugs and other treatment strategies are being investigated recently. Therefore, more experimental and clinical research is imperative to identify the mechanisms more clearly and to explore the best protocol of HBOT in stroke treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据